The Application of Clinical Genetics (Jul 2021)
Genetic Testing for Aneuploidy in Patients Who Have Had Multiple Miscarriages: A Review of Current Literature
Abstract
Ralph S Papas,1 William H Kutteh2,3 1Department of Obstetrics and Gynecology, Saint George Hospital - University Medical Center, Beirut, Lebanon; 2Department of Obstetrics and Gynecology, Baptist Memorial Hospital, Memphis, TN, USA; 3Recurrent Pregnancy Loss Center, Fertility Associates of Memphis, Memphis, TN, USACorrespondence: William H KuttehRecurrent Pregnancy Loss Center, Fertility Associates of Memphis, 80 Humphreys Center, Suite 307, Memphis, TN, 38139, USATel +1 901-747-2229Fax +1 901-747-4446Email [email protected]: Recurrent pregnancy loss (RPL) is an obstetrical complication that affects about 3% of reproductive age couples. Genetic and non-genetic causes of RPL are multiple; however, aneuploidy is the most common obstetrical complication that can explain single and recurrent pregnancy loss (present in about 60% of recognized clinical pregnancies which result in a miscarriage). Parental karyotyping will only be of potential benefit for 2 to 5 percentage of RPL couples who are translocation carriers. Products of conception (POC) karyotype analysis has been used to direct management in RPL and has been shown to be cost-effective, but the technique has many limitations including high culture failure rate and maternal cell contamination. These limitations can be significantly reduced using POC chromosomal microarray (CMA) technology. We believe that POC genetic testing should be performed after the second and subsequent pregnancy loss using CMA. Although the results will not generally alter the course of treatment, the knowledge of the reason for the loss is of great emotional comfort to many patients. In addition, POC CMA performed in conjunction with a regular complete maternal RPL work-up will identify the group of truly unexplained RPL. Thus, only 10% of patients with RPL will complete an evaluation having a euploid loss and an otherwise normal work-up. This group of “truly unexplained RPL” would be ideal for new research trials and therapies. Pre-implantation genetic testing (PGT) technology has improved recently with day 5 trophectoderm biopsy as compared to biopsy on day 3 as well as with the addition of CMA and next-generation sequencing technologies. The most recent studies on PGT-SR (PGT-Structural rearrangement) show improved clinical and live birth rates per pregnancy, as well as decreased miscarriage rate for translocation carriers. PGT-A (PGT-aneuploidy) may have a limited role in RPL in cases with documented recurrent POC aneuploidy.Keywords: karyotype, products of conception, chromosomal microarray analysis, aneuploidy, pre-implantation genetic testing, recurrent pregnancy loss
